MAZE THERAPEUTICS, INC. (MAZE) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $56.00K; Additional Paid in CapitalUSD $1.01B; AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD $-435.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $50.00K; Additional Paid in CapitalUSD $855.54M; AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD $-135.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $49.00K; Additional Paid in CapitalUSD $844.35M; AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD $110.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $48.00K; Additional Paid in CapitalUSD $834.30M; AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD $69.00K.
MAZE THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $56.00K | $1.01B | $-435.00K | $-558.48M | $453.12M | $453.12M | 3 month · $9.19M |
| 2026-03-31 | $0.00 | $50.00K | $855.54M | $-135.00K | $-513.75M | $341.70M | $341.70M | 3 month · $7.11M |
| 2025-12-31 | $0.00 | $49.00K | $844.35M | $110.00K | $-489.55M | $354.97M | $354.97M | 12 month · $16.40M |
| 2025-09-30 | $0.00 | $48.00K | $834.30M | $69.00K | $-454.98M | $379.44M | $379.44M | 3 month · $3.86M |
| 2025-06-30 | $0.00 | $44.00K | $687.09M | (m) | $-424.89M | $262.24M | $262.24M | 3 month · $3.24M |
| 2025-03-31 | (m) | $44.00K | $683.24M | (m) | $-391.21M | $292.07M | $292.07M | 3 month · $3.23M |
| 2024-12-31 | $0.00 | $2.00K | $47.24M | (m) | $-358.43M | $-311.18M | $-311.18M | 12 month · $9.65M |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | $-284.53M | 3 month · $2.34M |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | $-262.37M | 3 month · $2.14M |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | $-403.66M | 3 month · $2.31M |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $-373.85M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |